MS, Diabetes Groups Form Partnership With Italian Biotech In Drug-Discovery Effort
This article was originally published in The Pink Sheet Daily
Executive Summary
Axxam will seek to discover ion channel modulators that show potential efficacy in type 1 diabetes and/or multiple sclerosis.
You may also be interested in...
EMD Serono Buys $19M Seat At MS Society’s Research Table
Unlike some other industry/charity couplings, pharma foots the VC bill.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.